News & Events

Learn about what's new with CMC Biologics

Bob Broeze

SVP Business Development

Recent Posts by Bob Broeze:

Biotech Showcase 2019, January 7-9, San Francisco, CA


Biotech ShowcasePlease join us at Biotech Showcase in San Francisco in January. 

 Email us at to set up a meeting.


AGC Biologics Adds Mammalian Production Capacity in Japan


New facility will include comprehensive mammalian process development and manufacturing capabilities

BOTHELL, WA and CHIBA, JAPAN; Sept 20, 2018 ─ AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other
types of therapeutic proteins.

AGC Biologics Expands Capacity at Copenhagen, Denmark Facility


Strategic expansion will meet increasing global demand for biopharmaceutical development and manufacturing 

COPENHAGEN, Denmark and BOTHELL, Wash., 
Aug. 22, 2018
 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its global expansion strategy, the company is increasing manufacturing capacity at its Copenhagen, Denmark facility. 

Achieving Continuous Downstream Bioprocessing

Thought Leadership


In this article, Michelle Najera, PhD., Downstream Process Development Scientist for CMC Biologics, discusses how multi-column chromatography (MCC) technology offers prominent productivity gains and economic advantages for downstream bioprocessing. 

CMC Biologics Participates in Denmark State Visit to Korea


CMC Biologics Copenhagen Facility site head Patricio Massera, was honored to participate in the recent Danish State Visit to Korea

CMC Biologics was chosen for inclusion in the state visit, along with representatives from other select Danish companies in the Health Industry, for participation in a Denmark- Korea Roundtable Meeting on Health.

CMC Biologics and IDT Biologika Announce the Addition of Cerbios-Pharma and Oncotec Pharma to their Strategic Collaboration


Cerbios-Pharma will Provide Highly Cytotoxic Drug Payloads and Conjugation Services for Manufacture of ADC Drug Substance

Oncotec Pharma will Provide Sterile Filling and Lyophilization of Cytotoxic Active Ingredients for ADCs

CMC Biologics Cleared for Commercial Manufacture of CSL Behring's FDA-Approved AFSTYLA®


Bulk Drug Intermediate Produced in CMC Biologics’ Copenhagen, Denmark Facility

COPENHAGEN, Denmark and BOTHELL, Wash. – June 16, 2016 CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, today announced that it will supply bulk drug intermediate for CSL Behring’s recently FDA-approved product, AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A, to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and the perioperative management of bleeding.

View or Download as a PDF  

CMC Biologics Expands GMP Manufacturing Capacity in Europe


Addition of a Bioreactor 3PACK™ Production Facility to its Copenhagen Facility Provides Additional Flexible Soultions for Clients

BOTHELL, Wash., Berkeley, Calif., USA, and COPENHAGEN, Denmark – June 2, 2016 (GLOBE NEWSWIRE) – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, announced today that, as part of its ongoing global manufacturing capacity expansion, it has completed the first stage of the expansion for its manufacturing facility in Copenhagen, Denmark with the addition of a single-use Bioreactor 3PACK™ facility. The Bioreactor 3PACK™ configuration consists of three 2,000L single-use production bioreactors and associated seed train for scale up, allowing for flexible production with scales from 2,000L to 6,000L in a single production suite. The bioreactors can be run singly, simultaneously, sequentially or in staggered fashion to achieve desired production needs. The 3PACK™ line is ready for production runs in June 2016.

View or Download as a PDF  

Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst's Next-Generation Factor VIIa Product CB 813d


Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor Vlla CB 813d

Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B "Inhibitor" Patients in 2017

SOUTH SAN FRANCISCO, Calif. and BOTHELL, Wash. and COPENHAGEN, Denmark – May 24, 2016 (GLOBE NEWSWIRE) – Catalyst Biosciences, Inc. (NASDAQ:CBIO), a leading biotechnology company focused on discovering and developing novel protease therapeutics for treatments of serious medical conditions in the fields of hemostasis and anti-complement, and CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of CB 813d, Catalyst’s next-generation long-acting Factor VIIa product. Catalyst is developing CB 813d for the treatment of hemophilia A and B inhibitor patients.

View or Download as a PDF  

CMC Biologics Recognized as a Leader in Contract Development and Manufacturing by Customers and the Biopharmaceutical Industry


Life Science Leader Awards CMC Biologics for it Quality, Reliability, Capabilities, Expertise, Compatibility, State-of-the-Art and Innovation

SEATTLE, WA, BERKELEY, CA, and COPHENHAGEN, DENMARK – March 29, 2016 CMC Biologics, Inc., a world leader in contract development and manufacturing of therapeutic proteins, today announced its recognition by Life Science Leader in their CMO Leadership Award Ceremony. The ceremony, which took place in New York on March 16, 2016, recognized CMC Biologics as the leader in all five categories—Quality, Reliability, Capabilities, Expertise and Compatibility.

Follow Us
Join us on LinkedIn Follow us on Twitter